DCM is the leading cause of death in Duchenne patients. LVADs are considered as therapeutic options as DT in advanced HF. The aim of our study was to evaluate LV remodeling of Duchenne after LVADs and chronic therapy. Demographic and echocardiographic data of 8 Duchenne patients implanted with LVADs were reviewed and analyzed. All measures were collected before LVAD implantation, after 1 month and 1 year. All patients were affected by end‐stage DCM, and mean age at implantation was 16.9 ± 2.9 years. Patients were treated with maximal medical therapy. One‐year post‐implantation HR decreased from a mean of 110 ± 19 bpm to 82 ± 2 bpm (P = .002), and a significant decrease in LV volumes and diameters LVEDD P = .03, LVESD P = .02, EDV P = .01, and ESV P = .02) was noticed together with a significant increase in EF (P = .0036). However, RWT did not change over time, showing an eccentric remodeling pattern pre‐ and post‐LVADs. Our data showed that cardiac atrophy is persistent in Duchenne cardiomyopathy despite the improvement of LV function secondary to a significant ventricular unloading due to LVADs coupled with chronic therapy.
[1]
A. Amodeo,et al.
Left ventricular assist device as destination therapy in cardiac end‐stage dystrophinopathies: Midterm results
,
2017,
The Journal of thoracic and cardiovascular surgery.
[2]
E. Hoffman,et al.
Contemporary Cardiac Issues in Duchenne Muscular Dystrophy
,
2015,
Circulation.
[3]
H. Kim,et al.
Myocardial atrophy in children with mitochondrial disease and Duchenne muscular dystrophy
,
2014,
Korean journal of pediatrics.
[4]
A. Amodeo,et al.
Left ventricular assist device in Duchenne cardiomyopathy: can we change the natural history of cardiac disease?
,
2012,
International journal of cardiology.
[5]
W. Gaasch,et al.
Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry.
,
2011,
Journal of the American College of Cardiology.